Analysis Life Sciences: FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity
Agency IQ
JUNE 9, 2023
FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity Late last week the FDA released a final guidance document containing recommendations on the nonclinical assessment of potential immunotoxicity for drugs and certain biologics. What are nonclinical studies and when are they conducted in drug development?
Let's personalize your content